Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15543 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Gabriel P A Costa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ribeirão Preto, Ribeirão Preto, Brazil. Hauptthemen laut MEDLINE: Topiramate, Weight Gain, Antipsychotic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aims
To conduct a systematic review and meta‐analysis with the aim of synthesizing existing data on the efficacy and safety of topiramate as an adjunctive treatment for reducing second‐generation antipsychotic (SGA)‐associated weight gain in children aged 4–18 years.
Methods
We conducted a comprehensive search of PubMed, Embase, PsychNet and Web of Science from time of their inception up to 12 February 2024, including randomized controlled trials that compared SGA treatment with and without topiramate co‐administration in children. The primary outcomes were changes in body weight and body mass index (BMI). Heterogeneity was assessed using I 2 statistics.
Results
This systematic review included five randomized trials, totalling 139 participants (43.9% female; mean [SD] age 11.9 [3.5] years). Four of these trials were included in the meta‐analysis, comprising 116 subjects. We found that topiramate was significantly effective both in reducing SGA‐associated weight gain, with a mean difference of −2.80 kg (95% confidence interval [CI] −5.28 to −0.31; p = 0.037, I 2 = 86.7%) and a standardized mean difference (SMD) of −1.33 (95% CI −2.14 to −0.51; p = 0.014, I 2 = 31.7%), and in reducing BMI change compared to placebo (SMD −1.90, 95% CI −3.09 to −0.70; p = 0.02, I 2 = 0%). Sedation risk was lower with topiramate than with placebo (odds ratio 0.19, 95% CI 0.11–0.32; p < 0.01, I 2 = 0%). No significant differences were found in dropouts, any other side effects, and metabolic parameters, such as triglycerides, total cholesterol, low‐density lipoprotein, high‐density lipoprotein, and glucose. None of the included studies reported assessments on cognitive side effects.
Conclusion
This meta‐analysis suggests that topiramate is an effective and safe option for mitigating SGA‐associated weight gain in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Ribeirão Preto, Ribeirão Preto, Brazil.
- Faculty of Medicine, Evangelical University of Goias, Anápolis, Brazil.
- Department of Endocrinology, University of São Paulo, Ribeirão Preto, Brazil.
- Department of Psychiatry and Psychology, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Psychiatry, University Hospitals Medical Center, Cleveland, Ohio, USA.
ORCID-Profile: Gabriel P A Costa, Beatriz R Assunção, Julio C Nunes
Zitieren
APA
Costa, G. P. A., Moraes, V. R. Y., Assunção, B. R., Burns, N., Laique, S., Sengupta, S., Anand, A., & Nunes, J. C. (2024). Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15543
Vancouver
Costa GPA, Moraes VRY, Assunção BR, Burns N, Laique S, Sengupta S, et al. Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15543
BibTeX
@article{Costa2024,
author = {Costa, Gabriel P A and Moraes, Vitor R Y and Assunção, Beatriz R and Burns, Nora and Laique, Sobia and Sengupta, Shreya and Anand, Akhil and Nunes, Julio C},
title = {Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15543}
}
EUVIMED